These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 19120084)

  • 1. Belatacept as maintenance immunosuppression for postrenal transplant de novo drug-induced thrombotic microangiopathy.
    Ashman N; Chapagain A; Dobbie H; Raftery MJ; Sheaff MT; Yaqoob MM
    Am J Transplant; 2009 Feb; 9(2):424-7. PubMed ID: 19120084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful conversion to belatacept after thrombotic microangiopathy in kidney transplant patients.
    Koppula S; Yost SE; Sussman A; Bracamonte ER; Kaplan B
    Clin Transplant; 2013; 27(4):591-7. PubMed ID: 23923969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thrombotic microangiopathy associated with combined sirolimus and tacrolimus immunosuppression after intestinal transplantation.
    Paramesh AS; Grosskreutz C; Florman SS; Gondolesi GE; Sharma S; Kaufman SS; Fishbein TM
    Transplantation; 2004 Jan; 77(1):129-31. PubMed ID: 14724447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biological agents in kidney transplantation: belatacept is entering the field.
    Wéclawiak H; Kamar N; Ould-Mohamed A; Cardeau-Desangles I; Rostaing L
    Expert Opin Biol Ther; 2010 Oct; 10(10):1501-8. PubMed ID: 20726688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A network meta-analysis of the efficacy of belatacept, cyclosporine and tacrolimus for immunosuppression therapy in adult renal transplant recipients.
    Goring SM; Levy AR; Ghement I; Kalsekar A; Eyawo O; L'Italien GJ; Kasiske B
    Curr Med Res Opin; 2014 Aug; 30(8):1473-87. PubMed ID: 24628478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclosporine and tacrolimus-associated thrombotic microangiopathy.
    Pham PT; Peng A; Wilkinson AH; Gritsch HA; Lassman C; Pham PC; Danovitch GM
    Am J Kidney Dis; 2000 Oct; 36(4):844-50. PubMed ID: 11007689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of belatacept to maintain adequate early immunosuppression in calcineurin-mediated microangiopathic hemolysis post-renal transplant.
    Reynolds BC; Talbot D; Baines L; Brown A
    Pediatr Transplant; 2014 Aug; 18(5):E140-5. PubMed ID: 24815506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased risk of thrombotic microangiopathy in patients receiving a cyclosporin-sirolimus combination.
    Fortin MC; Raymond MA; Madore F; Fugère JA; Pâquet M; St-Louis G; Hébert MJ
    Am J Transplant; 2004 Jun; 4(6):946-52. PubMed ID: 15147429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [De novo hemolytic uremic syndrome in a kidney-pancreas recipient in the postoperative period].
    Gutiérrez de la Fuente C; Sola E; Alférez MJ; Navarro A; Cabello M; Burgos D; González Molina M
    Nefrologia; 2004; 24 Suppl 3():3-6. PubMed ID: 15219059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal transplantation using belatacept without maintenance steroids or calcineurin inhibitors.
    Kirk AD; Guasch A; Xu H; Cheeseman J; Mead SI; Ghali A; Mehta AK; Wu D; Gebel H; Bray R; Horan J; Kean LS; Larsen CP; Pearson TC
    Am J Transplant; 2014 May; 14(5):1142-51. PubMed ID: 24684552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. De novo donor-specific antibodies in belatacept-treated vs cyclosporine-treated kidney-transplant recipients: Post hoc analyses of the randomized phase III BENEFIT and BENEFIT-EXT studies.
    Bray RA; Gebel HM; Townsend R; Roberts ME; Polinsky M; Yang L; Meier-Kriesche HU; Larsen CP
    Am J Transplant; 2018 Jul; 18(7):1783-1789. PubMed ID: 29509295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Three-year outcomes from BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys.
    Pestana JO; Grinyo JM; Vanrenterghem Y; Becker T; Campistol JM; Florman S; Garcia VD; Kamar N; Lang P; Manfro RC; Massari P; Rial MD; Schnitzler MA; Vitko S; Duan T; Block A; Harler MB; Durrbach A
    Am J Transplant; 2012 Mar; 12(3):630-9. PubMed ID: 22300431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rationale for using belatacept in combination with sirolimus.
    Wéclawiak H; Kamar N; Ould-Mohamed A; Cardeau-Desangles I; Rostaing L
    Transplant Proc; 2010 Nov; 42(9 Suppl):S29-31. PubMed ID: 21095447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients.
    Ferguson R; Grinyó J; Vincenti F; Kaufman DB; Woodle ES; Marder BA; Citterio F; Marks WH; Agarwal M; Wu D; Dong Y; Garg P
    Am J Transplant; 2011 Jan; 11(1):66-76. PubMed ID: 21114656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sirolimus-induced thrombotic microangiopathy in a renal transplant recipient.
    Barone GW; Gurley BJ; Abul-Ezz SR; Gökden N
    Am J Kidney Dis; 2003 Jul; 42(1):202-6. PubMed ID: 12830473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Belatacept: a new biologic and its role in kidney transplantation.
    Su VC; Harrison J; Rogers C; Ensom MH
    Ann Pharmacother; 2012 Jan; 46(1):57-67. PubMed ID: 22215686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of posttransplant lymphoproliferative disorder associated with use of belatacept.
    Martin ST; Powell JT; Patel M; Tsapepas D
    Am J Health Syst Pharm; 2013 Nov; 70(22):1977-83. PubMed ID: 24173007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Belatacept: a novel biologic for maintenance immunosuppression after renal transplantation.
    Martin ST; Tichy EM; Gabardi S
    Pharmacotherapy; 2011 Apr; 31(4):394-407. PubMed ID: 21449628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Belatacept-based immunosuppression in de novo liver transplant recipients: 1-year experience from a phase II randomized study.
    Klintmalm GB; Feng S; Lake JR; Vargas HE; Wekerle T; Agnes S; Brown KA; Nashan B; Rostaing L; Meadows-Shropshire S; Agarwal M; Harler MB; Garcia-Valdecasas JC
    Am J Transplant; 2014 Aug; 14(8):1817-27. PubMed ID: 25041339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thrombotic microangiopathy in marginal kidneys after sirolimus use.
    Pellé G; Xu Y; Khoury N; Mougenot B; Rondeau E
    Am J Kidney Dis; 2005 Dec; 46(6):1124-8. PubMed ID: 16310579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.